How Nobel Prize-Winning Optogenetics Has Revolutionized Neuroscience
Gladstone's Jeanne Paz reflects on her early-career years in the lab of 2026 Nobel Prize winner Karl Deisseroth and explains how optogenetics has advanced epilepsy research.
The Technologies We’re Developing
At Gladstone, we not only use the latest technology—we build it.
From AI models to novel vaccine approaches, our scientists are creating bleeding-edge computational tools and molecular technologies to accelerate research across every disease area. Our researchers also continue to build on iPS cells and CRISPR, technologies pioneered by scientists who now call Gladstone home, pushing even further the boundaries of what’s possible in science.
Phage Therapy
Scientists at Gladstone are developing new ways to engineer and optimize phages to counter drug-resistant infections, which represent one of the world’s most urgent health threats.
iPS Cells
One of the most important advances in modern biomedical research, iPS cells help Gladstone researchers study disease, screen drugs, and develop potential cell therapies.
Artificial Intelligence
At Gladstone, our scientists are creating some of the world’s most advanced AI models in biomedical research—allowing both experiments in living cells and AI itself to advance faster.
CRISPR Genome Editing
Gladstone researchers are using CRISPR and advancing gene-editing approaches to better understand disease, develop new diagnostics, and design next-generation therapies.
Vaccine Innovation
At Gladstone, scientists are developing innovative vaccines that generate better immune responses to respond to future pandemics and some of medicine’s greatest unmet challenges.
Related News
Read
How AI Could Usher in a ‘New Scientific Golden Age’—If It Doesn’t Kill Us All First
Gladstone Investigator Steve Finkbeiner discusses the remarkable potential of AI to advance science—and the risk of too-stringent government regulations on AI hampering discovery.
Read
Voices: What Impact Has Ipsc Technology Had on Your Research And/or Field?
Induced pluripotent stem cell technology has already opened countless new possibilities for treating disease, but Gladstone Investigator Shinya Yamanaka says he believes the best is yet to come.
Read
Topos Bio Launches Two AI Models for Hard-to-Target Proteins
The company has been working with Steve Finkbeiner's team at Gladstone since January to search for molecules targeting alpha-synuclein, a protein involved in Parkinson's disease.
Read
Anthropic Says It Discovered a CRISPR-Like System. Now What?
Gladstone Associate Investigator Seth Shipman says Anthropic's discovery of an enzyme system is interesting, but cautions against attributing the scientific work entirely to an AI model.
Get Involved
Join the Team
Our people are our most important asset. We offer a wide array of career opportunities both in our administrative offices and in our labs.
Open PositionsPartner With Us
Discoveries don’t stay in our labs. Gladstone facilitates spinout companies to advance promising therapies, shortening the path between scientific discovery and helping real patients.
Learn MoreGive
Your gift to Gladstone will allow our researchers to pursue high-quality science, focus on disease, and train the next generation of scientific thought leaders.
Donate Now